Changes of hepatic vitronectin levels in patients with chronic hepatitis C treated with interferon alpha.
Hepatic vitronectin expression was assessed in 27 patients with chronic hepatitis C before and after interferon alpha treatment and in 7 control patients. Before interferon therapy, vitronectin was localized in the hepatocytes and in the portal and central venous regions. A high correlation was found for the vitronectin expression level with the histological grading and staging scores in the hepatocytes as well as in the portal region. After interferon therapy, the hepatic vitronectin was significantly decreased in the sustained and transient responders, but it was not as markedly decreased in the nonresponders and the non-treated group. A good correlation was found for the vitronectin expression with the staging scores but not with the grading scores in the portal region. These findings suggest that hepatic vitronectin is influenced by interferon therapy and that it may play an important role as a hepatic adhesion molecule through the improvement of inflammation, necrosis and fibrogenesis.
Yamada
S
S
Tottori University College of Medical Care Technology, Yonago, Japan.
Suou
T
T
Kawasaki
H
H
Horie
Y
Y
Nagami
M
M
Yashima
S
S
Sugihara
C
C
Tanaka
H
H
D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D016898:Interferon-alpha / Q000627:therapeutic use*; D008099:Liver / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D019096:Vitronectin / Q000378:metabolism*
D000998:Antiviral Agents; D016898:Interferon-alpha; D019096:Vitronectin